IMR Press / EJGO / Volume 32 / Issue 6 / pii/1630981971227-1954493032

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
The treatment of uterine leiomyosarcoma: Clinical outcomes of 18 cases and the effectiveness of chemotherapy
Show Less
1 Department of Gynecology, Cancer Institute Hospital, Ariake, Koutou-ku, Tokyo (Japan)
Eur. J. Gynaecol. Oncol. 2011, 32(6), 647–650;
Published: 10 December 2011

Purpose: To investigate clinical outcomes with respect to the effectiveness of chemotherapy in the treatment of uterine leiomyosarcoma. Methods: Study subjects were 18 patients with uterine leiomyosarcoma treated surgically at our hospital between February 1986 and December 2007. A chemotherapy regimen that combined ifosfamide, epirubicine, and cisplatin (IEP) was used as the main first-line chemotherapy. Results: FIGO disease stages were as follows: Stage I (n = 11), Stage II (n = 1), Stage III (n = 3), Stage IV (n = 3). Five-year overall survival of patients with Stage I-III disease was 65.3% (95% CI: 46.1-92.4%). None of patients with Stage IV disease survived for more than two years. Of seven patients who suffered advanced or recurrent disease, six received IEP; the response rate was 50%, one complete response and two partial responses. Conclusions: The combination of surgery and chemotherapy seems to be an acceptable treatment for uterine leiomyosarcoma. IEP may be an active regimen for this aggressive disease.
Uterine leiomyosarcoma
Response rate
Back to top